gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLC10.22416/1382-4376-2018-28-3-54-62gastro-j-241Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL ARTICLESТечение хронических воспалительных заболеваний кишечника и методы их лечения, применяемые в Российской Федерации(Результаты многоцентрового популяционного одномоментного наблюдательного исследования)Chronic inflammatory bowel diseases: the course and treatment methods in Russian Federation (Results of multicenter population-based one-stage observational study)ХалифИ. Л.KhalifL. .noemail@neicon.ruШапинаМ. В.ShapinaM. V.noemail@neicon.ruГоловенкоА. О.GolovenkoA. O.noemail@neicon.ruБелоусоваЕ. А.BelousovaYe. A.noemail@neicon.ruЧашковаЕ. Ю.ChashkovaYe. Yu.noemail@neicon.ruЛахинА. В.LakhinA. V.noemail@neicon.ruКнязевО. В.KnyazevO. V.noemail@neicon.ruБарановскийА. Ю.BaranovskyA. Yu.noemail@neicon.ruНиколаеваН. Н.NikolayevaN. N.noemail@neicon.ruТкачевА. В.TkachevA. V.noemail@neicon.ruГосударственный научный центр колопроктологииРоссияState Coloproctology Research CenterRussian FederationМосковский областной научно-исследовательский клинический институт им. М.Ф. ВладимирскогоРоссияMoscow Regional Research and Clinical InstituteRussian FederationИркутский научный центр хирургии и травматологииРоссияIrkutsk scientific center of surgery and traumatologyRussian FederationЛипецкая областная клиническая больницаРоссияLipetsk regional hospitalRussian FederationМосковский клинический научный центрРоссияMoscow clinical scientific centerRussian FederationГородская клиническая больница № 31РоссияCity hospital #31Russian FederationКрасноярский государственный медицинский университет им. проф. В.Ф. Войно-ЯсенецкогоРоссияVoyno-Yasenetsky Krasnoyarsk state medical universityRussian FederationФГБОУ ВО «Ростовский государственный медицинский университет»РоссияRostov State Medical UniversityRussian Federation2018120820182835462Copyright © Халиф И.Л., Шапина М.В., Головенко А.О., Белоусова Е.А., Чашкова Е.Ю., Лахин А.В., Князев О.В., Барановский А.Ю., Николаева Н.Н., Ткачев А.В., 20182018Халиф И.Л., Шапина М.В., Головенко А.О., Белоусова Е.А., Чашкова Е.Ю., Лахин А.В., Князев О.В., Барановский А.Ю., Николаева Н.Н., Ткачев А.В.Khalif L..., Shapina M.V., Golovenko A.O., Belousova Y.A., Chashkova Y.Y., Lakhin A.V., Knyazev O.V., Baranovsky A.Y., Nikolayeva N.N., Tkachev A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/241

Цель исследования. Провести оценку распространенности клинических проявлений и вариантов лечения язвенного колита (ЯК) и болезни Крона (БК) в Российской Федерации. Материал и методы. Настоящее исследование является популяционным одномоментным наблюдательным. Из 8 гастроэнтерологических центров получены данные о пациентах с воспалительными заболеваниями кишечника (ВЗК), методах их лечения, результатах лабораторных исследований и частоте возникновения нежелательных явлений. Степень тяжести заболевания оценивал врач. Кодирование сопутствующих лекарственных препаратов, осложнений и системных проявлений проведено согласно MedDRA. Результаты. В исследование были включены 1000 пациентов (667 с ЯК, 333 с БК). У большинства пациентов наблюдалось хроническое рецидивирующее (53,1% с ЯК, 45,0% с БК) или хроническое непрерывное (32,8% с ЯК, 39,65 с БК) течение заболевания, легкая атака отмечена у 51,3% пациентов с ЯК и 52,3% - с БК, атака средней степени тяжести - у 46,6 и 47,3% соответственно. Системные проявления и осложнения заболевания выявлены у 33,5% пациентов. На момент набора в исследование больные получали лекарственные препараты в рамках поддерживающей терапии, чаще всего препараты 5-аминосалициловой кислоты (72,0% с ЯК, 59,5% с БК) и иммуносупрессоры (28,0% с ЯК, 42,6% с БК); биологические препараты назначали редко (11,75% с ЯК, 20,4% с БК). Оперативное вмешательство ранее выполнено 43,8% пациентам с БК и 5,7% - с ЯК. Медиана (диапазон) количества госпитализаций составляла 1 (1-10) у пациентов с ЯК и 1 (1-24) у пациентов с БК. Выводы. Высокая частота возникновения осложнений, выполнения оперативных вмешательств и изменения терапии свидетельствует о том, что подходы к лечению данной когорты больных с ВЗК в Российской Федерации недостаточно оптимальны.

Aim of investigation. To evaluate the prevalence of clinical manifestations and variants of progression for ulcerative colitis (UC) and Crohn’s disease (CD) in population of the Russian Federation. Material and methods. The present investigation was designed as population-based one-stage observational study. The clinical data, treatment methods, laboratory tests results and the rate of adverse effects for patients with inflammatory bowel diseases (IBD) from 8 gastroenterological centers were obtained. Severity grade was estimated by a doctor. Encoding of concurrent therapy, complications and systemic manifestations was carried out according to MedDRA. Results. Original study included overall 1000 patients (667 UC patients, 333 CD patients). Most of the study patients were diagnosed to have chronic relapsing (53.1% for UC; 45.0% for CD) or chronic persistent (32.8% with UC; 39.65 with CD) course of disease, mild attack was revealed in 51.3% of UC patients and 52.3% of CD patients, moderate attack in 46.6 and 47.3% respectively. Systemic manifestations and complications of the disease were found in 33.5% of patients. At the moment of enrollments to the study patients received maintenance therapy, most frequently - by the drugs containing 5-aminosalicylic acid (72.0% for UC, 59.5% for CD) and immunosuppressors (28.0% for UC, 42.6% for CD); biological agents are prescribed rarely (11.75% for UC, 20.4% for CD). Previous surgical intervention was present in the past history of 43.8% CD patients and 5.7% - UC patients. The median (range) hospital admissions was 1 (1-10) in those with UC and 1 (1-24) in those with CD. Conclusions. High complication rate, previous surgical intervention and changes of therapeutic tactics demonstrates that treatment approaches to this cohort of IBD patients in the Russian Federation are not optimal enough.

воспалительные заболевания кишечникаязвенный колитболезнь КроналечениедиагностикаReferencesVan Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G, Beaugerie L, Gomollon F, Hauser W, Herrlinger K, Oldenburg B, Panes J, Portela F, Rogler G, Stein J, Tilg H, Travis S, Lindsay J O, European C s, Colitis O. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis 2013; 7(1):1-33.Van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G, Beaugerie L, Gomollon F, Hauser W, Herrlinger K, Oldenburg B, Panes J, Portela F, Rogler G, Stein J, Tilg H, Travis S, Lindsay J O, European C s, Colitis O. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis 2013; 7(1):1-33.Van Assche G, Dignass A, Reinisch W, van der Woude C J, Sturm A, De Vos M, Guslandi M, Oldenburg B, Dotan I, Marteau P, Ardizzone A, Baumgart D C, D’Haens G, Gionchetti P, Portela F, Vucelic B, Soderholm J, Escher J, Koletzko S, Kolho K L, Lukas M, Mottet C, Tilg H, Vermeire S, Carbonnel F, Cole A, Novacek G, Reinshagen M, Tsianos E, Herrlinger K, Oldenburg B, Bouhnik Y, Kiesslich R, Stange E, Travis S, Lindsay J, European C s, Colitis O. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Special situations. J Crohns Colitis 2010; 4(1):63101.Van Assche G, Dignass A, Reinisch W, van der Woude C J, Sturm A, De Vos M, Guslandi M, Oldenburg B, Dotan I, Marteau P, Ardizzone A, Baumgart D C, D’Haens G, Gionchetti P, Portela F, Vucelic B, Soderholm J, Escher J, Koletzko S, Kolho K L, Lukas M, Mottet C, Tilg H, Vermeire S, Carbonnel F, Cole A, Novacek G, Reinshagen M, Tsianos E, Herrlinger K, Oldenburg B, Bouhnik Y, Kiesslich R, Stange E, Travis S, Lindsay J, European C s, Colitis O. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Special situations. J Crohns Colitis 2010; 4(1):63101.Dignass A, Lindsay J O, Sturm A, Windsor A, Colombel J F, Allez M, D’Haens G, D’Hoore A, Mantzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012; 6(10):9911030.Dignass A, Lindsay J O, Sturm A, Windsor A, Colombel J F, Allez M, D’Haens G, D’Hoore A, Mantzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012; 6(10):9911030.Dignass A, Van Assche G, Lindsay J O, Lemann M, Soderholm J, Colombel J F, Danese S, D’Hoore A, Gassull M, Gomollon F, Hommes D W, Michetti P, O’Morain C, Oresland T, Windsor A, Stange E F, Travis S P, European C s, Colitis O. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management. J Crohns Colitis 2010; 4(1):28-62.Dignass A, Van Assche G, Lindsay J O, Lemann M, Soderholm J, Colombel J F, Danese S, D’Hoore A, Gassull M, Gomollon F, Hommes D W, Michetti P, O’Morain C, Oresland T, Windsor A, Stange E F, Travis S P, European C s, Colitis O. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management. J Crohns Colitis 2010; 4(1):28-62.Molodecky N A, Soon I S, Rabi D M, Ghali W A, Ferris M, Chernoff G, Benchimol E I, Panaccione R, Ghosh S, Barkema H W, Kaplan G G. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142(1):46-54. e42; quiz e30.Molodecky N A, Soon I S, Rabi D M, Ghali W A, Ferris M, Chernoff G, Benchimol E I, Panaccione R, Ghosh S, Barkema H W, Kaplan G G. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142(1):46-54. e42; quiz e30.Burisch J, Pedersen N, Cukovic-Cavka S, Brinar M, Kaimakliotis I, Duricova D, Shonova O, Vind I, Avnstrom S, Thorsgaard N, Andersen V, Krabbe S, Dahlerup J F, Salupere R, Nielsen K R, Olsen J, Manninen P, Collin P, Tsianos E V, Katsanos K H, Ladefoged K, Lakatos L, Bjornsson E, Ragnarsson G, Bailey Y, Odes S, Schwartz D, Martinato M, Lupinacci G, Milla M, De Padova A, D’Inca R, Beltrami M, Kupcinskas L, Kiudelis G, Turcan S, Tighineanu O, Mihu I, Magro F, Barros L F, Goldis A, Lazar D, Belousova E, Nikulina I, Hernandez V, Martinez-Ares D, Almer S, Zhulina Y, Halfvarson J, Arebi N, Sebastian S, Lakatos P L, Langholz E, Munkholm P, EpiCom G. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut 2014; 63(4):588-97.Burisch J, Pedersen N, Cukovic-Cavka S, Brinar M, Kaimakliotis I, Duricova D, Shonova O, Vind I, Avnstrom S, Thorsgaard N, Andersen V, Krabbe S, Dahlerup J F, Salupere R, Nielsen K R, Olsen J, Manninen P, Collin P, Tsianos E V, Katsanos K H, Ladefoged K, Lakatos L, Bjornsson E, Ragnarsson G, Bailey Y, Odes S, Schwartz D, Martinato M, Lupinacci G, Milla M, De Padova A, D’Inca R, Beltrami M, Kupcinskas L, Kiudelis G, Turcan S, Tighineanu O, Mihu I, Magro F, Barros L F, Goldis A, Lazar D, Belousova E, Nikulina I, Hernandez V, Martinez-Ares D, Almer S, Zhulina Y, Halfvarson J, Arebi N, Sebastian S, Lakatos P L, Langholz E, Munkholm P, EpiCom G. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut 2014; 63(4):588-97.Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, van Blankenstein M. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996; 39(5):690-7.Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, van Blankenstein M. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996; 39(5):690-7.D’Inca R, Podswiadek M, Ferronato A, Punzi L, Salvagnini M, Sturniolo G C. Articular manifestations in inflammatory bowel disease patients: a prospective study. Dig Liver Dis 2009; 41(8):565-9.D’Inca R, Podswiadek M, Ferronato A, Punzi L, Salvagnini M, Sturniolo G C. Articular manifestations in inflammatory bowel disease patients: a prospective study. Dig Liver Dis 2009; 41(8):565-9.Lakatos L, Pandur T, David G, Balogh Z, Kuronya P, Tollas A, Lakatos P L. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol 2003; 9(10):2300-7.Lakatos L, Pandur T, David G, Balogh Z, Kuronya P, Tollas A, Lakatos P L. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol 2003; 9(10):2300-7.Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998; 42(3):387-91.Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998; 42(3):387-91.Russell A S. Arthritis, inflammatory bowel disease, and histocompatibility antigens. Ann Intern Med 1977; 86(6):820-1.Russell A S. Arthritis, inflammatory bowel disease, and histocompatibility antigens. Ann Intern Med 1977; 86(6):820-1.Vavricka S R, Brun L, Ballabeni P, Pittet V, Prinz Vavricka B M, Zeitz J, Rogler G, Schoepfer A M. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 2011; 106(1):110-9.Vavricka S R, Brun L, Ballabeni P, Pittet V, Prinz Vavricka B M, Zeitz J, Rogler G, Schoepfer A M. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 2011; 106(1):110-9.

The authors declare that there are no conflicts of interest present.